{"entity":{"id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","aka":["OPTIMUS"],"tldr":"A phase 2 trial of pembrolizumab in pancreatic cancer, run by TME Pharma AG, not yet recruiting.","summary":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer is a phase 2, interventional study registered as NCT04901741 by TME Pharma AG, with a registry enrolment figure of 60 participants, started 2026-01 and due to reach its primary completion in 2028-03. Interventions recorded: Olaptesed pegol; Pembrolizumab. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Go/no-go decision for a randomized expansion study. Pancreatic eligibility wording from the registry: \"* Patient with histologically or cytologically confirmed primary metastatic adenocarcinoma of the pancreas, who\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04901741","url":"https://clinicaltrials.gov/study/NCT04901741"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04901741","phase":"2","setting":"An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients","sponsor":"TME Pharma AG","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04901741/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}